Iampreechakul Prasert, Tirakotai Wuttipong, Lertbutsayanukul Punjama, Siriwimonmas Somkiet, Liengudom Anusak
J Med Assoc Thai. 2016 Jun;99 Suppl 3:S91-119.
To examine the safety and efficacy of pre-operative embolization of intra-and extracranial tumors and determine the selection criteria of patients for this procedure.
Between June 2008 and August 2012, 37 patients (17 males, 20 females; mean age, 44.2+14.2years), underwent pre-operative embolization of intra- and extracranial tumors, were retrospectively reviewed. Tumor characteristics (type, location, volume, percentage of supplying artery, presence of an early draining vein), angiographic extent of tumor devascularization, timing between embolization and surgery, estimated blood loss, and complication related embolization were evaluated.
There were 37 tumors (mean volume, 90.9+83.6 cm3) composed of 18 meningiomas, six hemangioblastomas, six hemangiopericytomas, one metastasis, one osteoblastoma, one osteosacroma, one neurofibroma, one central neurocytoma, one glomus jugulare, one mixed oligoastrocytoma, and one glioblastoma multiforme. Early of draining veins were visualized in 24 patients (64.9%). Failure of pre-operative embolization occurred in four patients. Median time to surgery after embolization was seven days (ranged 1-171 days). There was statistically significant difference between grading of angiographic devascularization and estimated blood loss (p = 0.009, Kruskal-Wallis test). Two patients (5.4%) had embolization-related complications, including hemorrhage during sub-selective catheterization and postoperative scalp necrosis.
Although pre-operative embolization of intra- and extracranial tumors was safe, only extensive or complete angiographic devascularization has been effective in less intra-operative blood loss. From this present study, indications regarding when to perform pre-operative embolization include history of excessive bleeding from previous surgery, known hypervascular tumor types (e.g., hemangiopericytoma, hemangioblastoma, paraganglioma), the presence of multiple flow voids on MRI, hypervascular tumors of skull or scalp, deep-seated tumors (e.g., cranial base tumor, intraventricular tumor) with difficulty in early surgical access of the main feeding vessels, and tumors associated with intratumoral aneurysm.
探讨术前栓塞颅内和颅外肿瘤的安全性和有效性,并确定该手术患者的选择标准。
回顾性分析2008年6月至2012年8月期间37例行术前栓塞颅内和颅外肿瘤的患者(男17例,女20例;平均年龄44.2±14.2岁)。评估肿瘤特征(类型、位置、体积、供血动脉百分比、早期引流静脉的存在情况)、肿瘤血管造影去血管化程度、栓塞与手术之间的时间间隔、估计失血量以及与栓塞相关的并发症。
共37个肿瘤(平均体积90.9±83.6 cm³),包括18例脑膜瘤、6例血管母细胞瘤、6例血管外皮细胞瘤、1例转移瘤、1例成骨细胞瘤、1例骨肉瘤、1例神经纤维瘤、1例中枢神经细胞瘤、1例颈静脉球瘤、1例混合性少突星形细胞瘤和1例多形性胶质母细胞瘤。24例患者(64.9%)可见早期引流静脉。4例患者术前栓塞失败。栓塞后至手术的中位时间为7天(范围1 - 171天)。血管造影去血管化分级与估计失血量之间存在统计学显著差异(p = 0.009,Kruskal - Wallis检验)。2例患者(5.4%)发生与栓塞相关的并发症,包括超选择性插管期间出血和术后头皮坏死。
虽然术前栓塞颅内和颅外肿瘤是安全的,但只有广泛或完全的血管造影去血管化才能有效减少术中失血量。根据本研究,术前栓塞的适应证包括既往手术有过多出血史、已知的高血运肿瘤类型(如血管外皮细胞瘤、血管母细胞瘤、副神经节瘤)、MRI上存在多个流空信号、颅骨或头皮的高血运肿瘤、早期难以手术暴露主要供血血管的深部肿瘤(如颅底肿瘤、脑室内肿瘤)以及与瘤内动脉瘤相关的肿瘤。